DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF
ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA

EQS-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous
DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF
ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA

08.07.2024 / 08:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

_________________________________________________________________

CSE: DTC FSE: DTC USOTC: DTCFF PRESS RELEASE

DEFENCE RECEIVES NO OBJECTION LETTER FROM HEALTH CANADA FOR PHASE I TRIAL OF
ITS ACCUM-002 (ACCUTOX) AS AN ANTI-CANCER MOLECULE IN PATIENTS WITH MELANOMA

Vancouver, BC, Canada, July 8th, 2024 - Defence Therapeutics Inc. ("Defence"
or the "Company"), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Canadian
biopharmaceutical company developing novel immune-oncology vaccines and drug
delivery technologies, is pleased to announce that it received a No
Objection Letter ("NOL") from Health Canada for its Clinical Trial Study
number ACCUM-002-01 entitles "A Phase I trial of Intratumoral Administration
of ACCUM-002TM as a Monotherapy and in Combination with Opdualag in Patients
with Unresectables, Stage IIIB and IV, Melanoma".

The primary objectives of this study are to determine the safety and
tolerability of intratumoral administration of AccuTOX®, as a monotherapy
and in combination with Opdualag which combines the LAG-3 checkpoint
inhibitor relatlimab and PD-1 inhibitor nivolumab. The secondary objectives
are to obtain preliminary efficacy data and to determine the Maximum
Tolerated Dose ("MTD") and recommended Phase 2 Dose ("RP2D") of AccuTOX®
exploits as immune booster and anti-cancer molecule.

According to Vision Research Reports, the global cancer immunotherapy market
size was estimated at USD 125.73 billion in 2023 and it is projected to
increase USD 280.11 billion by 2033 with a CAGR of 8.34% from 2024 to 2033.

https://www.biospace.com/article/releases/cancer-immunotherapy-market-size-to-increase-usd-280-11-bn-by-2033/

The Defence's team is already preparing this Phase I in Canada, most likely
to be conducted in both Quebec and Ontario from which the hospitals sites
will be confirmed upon agreements finalization.

"AccuTOX® is Defence's flagship asset in the anti-cancer therapeutics field
and this Phase I clinical trial shall demonstrate and confirm primarily its
safety and secondly its potency. We are thrilled to getting ready for this
Phase I in Canada. Defence remains committed to its mission of addressing
unmet clinical needs and in pursuing its goals to become a global leader in
the development of innovative anti-cancer therapies," said Sebastien
Plouffe, Chief Executive Officer of Defence Therapeutics.

About Defence:

Defence Therapeutics is a publicly-traded clinical-stage biotechnology
company working on engineering the next generation vaccines and ADC products
using its proprietary platform. The core of Defence Therapeutics platform is
the ACCUM® technology, which enables precision delivery of vaccine antigens
or ADCs inside target cells and favoring their processing and activities. As
a result, increased efficacy and potency can be reached against catastrophic
illness such as cancer and infectious diseases.

For further information:

Sebastien Plouffe, President, CEO and Director

P: (514) 947-2272

Splouffe@defencetherapeutics.com

www.defencetherapeutics.com

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking
statements". All statements in this release, other than statements of
historical facts, that address events or developments that the Company
expects to occur, are forward-looking statements. Forward-looking statements
are statements that are not historical facts and are generally, but not
always, identified by the words "expects", "plans", "anticipates",
"believes", "intends", "estimates", "projects", "potential" and similar
expressions, or that events or conditions "will", "would", "may", "could" or
"should" occur. Although the Company believes the expectations expressed in
such forward-looking statements are based on reasonable assumptions, such
statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that
could cause the actual results to differ materially from those in
forward-looking statements include regulatory actions, market prices, and
continued availability of capital and financing, and general economic,
market or business conditions. Investors are cautioned that any such
statements are not guarantees of future performance and actual results or
developments may differ materially from those projected in the
forward-looking statements. Forward-looking statements are based on the
beliefs, estimates and opinions of the Company's management on the date the
statements are made. Except as required by applicable securities laws, the
Company undertakes no obligation to update these forward-looking statements
in the event that management's beliefs, estimates or opinions, or other
factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the
policies of the CSE, accepts responsibility for the adequacy or accuracy of
this release.


---------------------------------------------------------------------------

08.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Defence Therapeutics Inc.
                   1680 - 200 Burrard St
                   V6C3L6 Vancouver
                   Canada
   E-mail:         info@defencetherapeutics.com
   Internet:       https://defencetherapeutics.com
   ISIN:           CA24463V1013
   WKN:            A3CN14
   Listed:         Regulated Unofficial Market in Frankfurt, Stuttgart;
                   Toronto
   EQS News ID:    1940821

End of News EQS News Service
---------------------------------------------------------------------------

1940821 08.07.2024 CET/CEST